Morgan Stanley F Star Therapeutics, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$4.09 - $6.86 $12,940 - $21,705	-3,164 Reduced 98.66%	43 $0
Q3 2022 Nov 14, 2022	SELL	$5.41 - $6.74 $38,016 - $47,361	-7,027 Reduced 68.66%	3,207 $16,000
Q2 2022 Oct 27, 2022	SELL	$2.18 - $6.39 $17,019 - $49,886	-7,807 Reduced 43.27%	10,234 $64,000
Q2 2022 Aug 15, 2022	SELL	$2.18 - $6.39 $17,019 - $49,886	-7,807 Reduced 43.27%	10,234 $64,000
Q1 2022 Oct 27, 2022	BUY	$2.77 - $5.36 $21,625 - $41,845	7,807 Added 76.28%	18,041 $64,000
Q1 2022 May 13, 2022	SELL	$2.77 - $5.36 $2,238 - $4,330	-808 Reduced 4.29%	18,041 $64,000
Q4 2021 Feb 14, 2022	BUY	$4.71 - $7.38 $46,968 - $73,593	9,972 Added 112.34%	18,849 $95,000
Q3 2021 Nov 15, 2021	BUY	$5.2 - $8.42 $46,160 - $74,744	8,877 New	8,877 $65,000

44.7K

Ticker FSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,584,700
Description
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.